SpringWorks Therapeutics shows strong growth with approved drugs and potential for more, making it a promising buy. Read my ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...

Brookline Capital Markets initiated coverage of Exelixis (EXEL) with a buy rating, highlighting the company's revenue ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

Fintel reports that on December 23, 2024, Brookline Capital initiated coverage of Exelixis (NasdaqGS:EXEL) with a Buy ...

Fintel reports that on December 20, 2024, BMO Capital downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Outperform ...

Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in ...

Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...

ALAMEDA, Calif., November 27, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor ...